NCT07217587 2026-03-13
EPIC
Janssen Research & Development, LLC
Phase 3 Recruiting
Clinical Trials
6 trialsNCT07072988 2025-09-24
OPTIMAGE
Centre Hospitalier Universitaire de Nice
Phase 4 Recruiting
NCT06765161 2025-07-29
Efgartigimod in IVIG Dependent Myasthenia Gravis Patients
Clinique Neuro-Outaouais
Phase 3 Recruiting
NCT02965573 2024-08-28
A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
argenx
Phase 2 Completed
NCT03770403 2023-07-14
ADAPT+
argenx
Phase 3 Completed
NCT03669588 2022-02-08
ADAPT
argenx
Phase 3 Completed